Overview

SBRT/LDRT in Combination With Camrelizumab and Apatinib in Metastatic Non-small Cell Lung Cancer Patient Previously Treated With PD-1/L1 Inhibitor and Chemotherapy

Status:
Recruiting

Trial end date:
2023-10-01

Target enrollment:

Participant gender:

Summary

SABRE STUDY will explore effectiveness and safety of the combination therapy of camrelizumab，apatinib and SBRT/LDRT in patients with metastatic non-small Cell Lung Cancer (NSCLC) patient previously treated With PD-1/L1 Inhibitor and Chemotherapy.

Phase:

Phase 2

Details

Lead Sponsor:

Wuhan University

Treatments:

Apatinib
Docetaxel